KOSDAQIT & Software032620

GC MediAI

₩2,870 0.00%2026-11-18 close
Market Cap
₩149.8B
Turnover
₩100M
Volume
40K
Shares out.
52.2M
PER
58.3×
PBR
1.0×
EPS
₩50
Dividend Yield
1.72%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit Recovery After Subsidiary Cleanup, Revenue Guidance Trimmed

GC MediAI is recovering operating profit as it exits loss-making subsidiaries and grows EMR add-on and platform revenue, although its 2026 revenue guidance was lowered after a narrower consolidation scope.

  1. 1

    Preliminary January–September 2026 results, announced by the company on November 9, 2026: revenue KRW 154.1 billion (up 6.5% year on year) and operating profit KRW 12.1 billion (up 165.9%).

  2. 2

    The 2026 operating profit guidance was raised from KRW 13.5 billion to KRW 17 billion, while the revenue guidance was cut from KRW 218.2 billion to KRW 174.4 billion, reflecting the removal of Hecton Project from consolidation.

  3. 3

    The AI clinical solution Uisarang AI, launched in August 2026, drew applications from more than 1,300 existing customers, with about 800 sites using it in clinics, and the company plans phased paid monetization from 2027.

  4. 4

    Net profit attributable to controlling shareholders swings sharply by quarter. A net loss of KRW 3.5 billion attributable to controlling shareholders was recorded in Q4 2025, and the four-quarter total from Q4 2025 to Q3 2026 is only KRW 2.6 billion.

  5. 5

    The debt ratio (total liabilities to total equity) was 43.3% at end-2025, and operating cash flow rose to KRW 16.6 billion in 2025, well above the KRW 4.25 billion, KRW 2.49 billion and KRW 2.35 billion recorded in 2022–2024.

02

Business structure

GC MediAI is described as the top provider of EMR systems for primary care clinics in Korea, and the company says its flagship EMR, Uisarang, is used by roughly 16,000 clinics and hospitals nationwide. The business spans four segments.

Medical Infra grows through add-on solution sales on its EMR base and higher average revenue per customer. Data & MKT sells the prescription data analytics service UBIST and related add-ons. Commerce runs the clinic-only platform Misomall.com, expanding brokered trade in pharmaceuticals and medical supplies.

Platform earns integration fees from external services such as the patient app Ddocdoc and insurance claim services, and Bibros, the operator of Ddocdoc, is now consolidated. Ddocdoc has been reported to have about 11 million verified members.

Subsidiary Crenner, a maker of automatic drug dispensing machines, has contributed to consolidated operating profit through cost reduction and overseas sales growth.

The company aims to build its EMR network into a Medical OS by connecting external services, and plans to open its roughly 16,000 clinics and hospitals and 8,300 pharmacies as a gateway for third-party services.

Meanwhile, Hecton Project, a 75%-owned subsidiary that ran a senior-care and welfare-equipment business, was removed from consolidated results after a partial business transfer.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩50.6B₩3B5.9%
2025Q4₩53.1B₩3B5.6%
2026Q1₩49.8B₩2.2B4.5%
2026Q2₩51.5B₩4B7.7%
2026Q3₩52.7B₩5.9B11.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩133.3B₩6.7B₩3.6B5.1%3.1%31.1%
2023₩154B₩3.5B-₩1.7B2.3%−1.6%36.5%
2024₩190.6B₩5.2B-₩1.6B2.7%−1.6%48.5%
2025₩197.7B₩7.5B₩37B3.8%26.1%43.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 133.3 billion in 2022 to KRW 154 billion in 2023 (up 15.5% year on year), KRW 190.6 billion in 2024 (up 23.7%) and KRW 197.7 billion in 2025 (up 3.7%), marking three consecutive years of growth from 2023 through 2025. Among 2022–2025, 2025 was the largest year and 2022 the smallest.

Operating profit fell from KRW 6.75 billion in 2022 to KRW 3.51 billion in 2023 (down 48.0%), which was the low point, and then grew for two consecutive years to KRW 5.16 billion in 2024 (up 47.1%) and KRW 7.52 billion in 2025 (up 45.7%).

The operating margin was 5.1% in 2022, 2.3% in 2023, 2.7% in 2024 and 3.8% in 2025, so margins stayed in the low single digits even in years of revenue growth. The CEO has said fixed costs kept operating margins at 3–4% under the traditional software distribution model (Herald Business report).

Net profit attributable to controlling shareholders was KRW 3.59 billion in 2022, turned to a net loss of KRW 1.71 billion in 2023, remained a loss of KRW 1.59 billion in 2024 with a smaller deficit, and returned to a profit of KRW 37 billion in 2025.

However, the 2025 figure of KRW 37 billion attributable to controlling shareholders, and KRW 37.8 billion in total net profit including non-controlling interests, is far larger than the KRW 7.52 billion operating profit of the same year.

Non-operating items or other one-off factors should be checked in the 2026 annual report notes.

At end-2025, total equity was KRW 158.9 billion, of which KRW 141.5 billion belonged to controlling shareholders, and total liabilities were KRW 68.8 billion; the debt ratio rose from 31.1% in 2022 to 48.5% in 2024 before easing to 43.3% in 2025.

Operating cash flow was KRW 4.25 billion in 2022, KRW 2.49 billion in 2023 and KRW 2.35 billion in 2024, then rose to KRW 16.6 billion in 2025.

Quarterly, operating profit held at KRW 2.99 billion in Q4 2025, yet a net loss of KRW 3.5 billion attributable to controlling shareholders appeared that quarter, which points to non-operating factors.

Revenue bottomed in Q1 2026 at KRW 49.8 billion (down 6.1% from the prior quarter) and operating profit at KRW 2.24 billion (down 24.9%), then recovered with operating profit of KRW 3.96 billion in Q2 and revenue of KRW 52.7 billion with operating profit of KRW 5.86 billion in Q3.

The Q3 2026 operating margin, calculated from revenue, was about 11.1%, compared with about 5.9% in Q3 2025. The preliminary January–September 2026 results announced on November 9, 2026, revenue KRW 154.1 billion and operating profit KRW 12.1 billion, are consistent with this quarterly pattern.

05

Industry analysis

The primary care EMR market in Korea is structured so that vendors grow revenue by layering add-on solutions, data services and platform services on an installed customer base.

According to the company, Uisarang EMR is used by about 16,000 clinics and hospitals nationwide, and this base is the starting point for add-on sales and higher average revenue per customer.

The repeated explanation in the January–September 2026 results is that growth from existing customers, rather than new installations, is what lifted earnings. In AI clinical tools, Uisarang AI, launched in August 2026, is spreading first among existing EMR customers.

On the platform side, the model of connecting external services to the EMR network and collecting fees is extending into pharmaceutical, financial, insurance and medical device areas.

Compared with large platform and system integration companies in the same IT and software sector, GC MediAI combines clinic-floor data with direct patient touchpoints. The CEO has pointed to data optimized for Korea's medical regulations and insurance environment as a strength (Herald Business report).

The CEO also said prescription and treatment data are trained and processed only within the company's own server infrastructure and are not sent to external servers. This setup could narrow the scope of external service integration if data regulation tightens.

Whether the EMR customer base works as a meaningful entry barrier can be gauged by how quickly customers move to the cloud EMR after its planned March 2027 launch.

06

Outlook

The company's 2026 operating profit guidance is KRW 17 billion, and given January–September operating profit of KRW 12.1 billion, about KRW 4.9 billion more is needed in Q4 (a calculated figure). In the same guidance, revenue was lowered to KRW 174.4 billion, reflecting the deconsolidation of Hecton Project.

The company expects profit growth to continue in the second half, led by Medical Infra and Commerce, and said it expects to exceed the existing operating profit guidance even after additional costs such as direct sales incentives (Press9 report).

Uisarang AI is planned to secure more than 6,000 adoption references by year-end 2026 before moving to phased paid monetization in 2027. A cloud-based EMR is scheduled for full launch in March 2027, alongside opening the nationwide clinic and pharmacy network as a gateway for third-party services.

A consumer-facing personal health assistant linked to Ddocdoc is planned for the second half of 2027 (Herald Business English report). The CEO has said he hopes annual operating profit will break KRW 20 billion in 2027, but this is a management aspiration rather than formal guidance.

The revenue model is moving from monthly maintenance fees toward higher-margin streams such as AI, data and external integration fees. The next checkpoints are the preliminary Q4 2026 results in early 2027 and the 2026 annual report in March 2027.

07

Valuation

PER
58.3×
PBR
1.0×
ROE
1.8%
EPS
₩50
BPS
₩2,902
Dividend per share
₩50

Multiples read differently depending on which earnings period is used. Net profit attributable to controlling shareholders turned to a profit of KRW 37 billion in 2025, but that figure is far above the same year's operating profit, so one-off items are likely involved.

The four-quarter total from Q4 2025 to Q3 2026 is only KRW 2.6 billion, so on that basis the share price is high relative to recent earnings. The gap between annual and last-four-quarter earnings is wide, so the direction of the multiple also depends on the period chosen.

On a price-to-book view, the share price sits near book value, and the market capitalization relative to equity attributable to controlling shareholders falls in the small-cap range on KOSDAQ. The company moved from losses in 2023 and 2024 to a profit in 2025, so its earnings track record is still short.

Some quarters have recovered, such as Q3 2026 net profit attributable to controlling shareholders of KRW 6.16 billion (up 230.6% year on year), but the sign has changed often, including the net losses in Q4 2025 and Q2 2026. The level of the multiple depends on whether the operating profit recovery continues across several quarters.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Operating profit recovery extending over several years

Annual operating profit bottomed at KRW 3.51 billion in 2023 and then grew for two consecutive years to KRW 5.16 billion in 2024 and KRW 7.52 billion in 2025.

Preliminary January–September 2026 operating profit, announced on November 9, 2026, was KRW 12.1 billion, up 165.9%, and the Q3 operating margin calculates to about 11.1%. The company attributes the improvement to subsidiary restructuring together with add-on solution sales in its core business.

AI and platform monetization on the EMR customer base

Uisarang AI was launched in August 2026, and more than 1,300 existing customers have applied, with about 800 sites already using it in clinical work. The company plans to secure more than 6,000 adoption references by year-end 2026 before phased paid monetization in 2027.

Integration fees from external services such as Ddocdoc, along with brokered trade on Misomall.com, are also growing as new revenue sources.

Subsidiary exit and a raised operating profit guidance

Hecton Project, a 75%-owned subsidiary, was removed from consolidated results after a partial business transfer, reducing the drag from its losses. According to a Herald Business report, the 2026 operating profit guidance was raised from KRW 13.5 billion to KRW 17 billion.

The CEO has said he hopes for annual operating profit above KRW 20 billion in 2027, and the higher guidance base points to room for operating margin improvement.

09

Bear factors

Slower top-line growth and a lower revenue guidance

Revenue growth slowed from 23.7% in 2024 to 3.7% in 2025, and cumulative January–September 2026 revenue grew only 6.5%. Q1 2026 revenue fell 6.1% from the prior quarter, and the 2026 revenue guidance of KRW 174.4 billion sits below 2025 revenue of KRW 197.7 billion. Part of the gap reflects deconsolidation, but the slow growth of the core top line remains a bearish point.

Quarterly earnings volatility and a thin recent profit base

Net profit attributable to controlling shareholders totaled KRW 2.6 billion over the last four quarters, from Q4 2025 to Q3 2026. A net loss of KRW 3.5 billion attributable to controlling shareholders appeared in Q4 2025, and a net loss of KRW 136 million appeared in Q2 2026.

Profit has not held steadily even in quarters with better operating profit, so non-operating items need to be verified, and the losses of 2023 and 2024 also shorten the earnings track record.

AI monetization is concentrated after 2027

Full monetization of Uisarang AI begins with the phased paid model from 2027, so paid revenue contribution to 2026 results is limited under that plan. The 6,000-site reference target for year-end 2026 is a company goal, and there is a wide gap from the roughly 800 sites in actual use. The cloud EMR is planned for March 2027, so it will not drive 2026 annual results.

10

Risk factors

Consolidation scope and subsidiary dependence

Revenue fell in consolidated terms after Hecton Project was removed, and Crenner's cost reduction and overseas sales as well as Bibros's Ddocdoc integration income were cited as main profit drivers. If subsidiary results weaken, gains in the core business could be offset. Further subsidiary divestments could change the reported revenue base again.

AI paid conversion and customer adoption

If the free-stage expansion of Uisarang AI does not convert into paid use from 2027, the monetization period will extend. Whether the 6,000-site reference target is met and what share of existing customers convert to paid use remain to be seen. The KRW 17 billion guidance requires about KRW 4.9 billion in Q4, so quarterly uncertainty also matters.

Medical data and regulatory environment

Because the business handles EMR, prescription and patient data, changes in personal data and medical information rules could shape its scope. The company says prescription and treatment data are processed within its own servers, but compliance demands may grow as external integrations expand.

As links to pharmaceutical, financial and insurance services widen, control of data flows becomes more important.

11

What to watch next

  1. End of December 2026

    Whether the target of more than 6,000 adoption references for Uisarang AI is reached. The gap from roughly 800 sites in active use will indicate the pace for the 2027 paid model.

  2. Early 2027

    The preliminary Q4 2026 results. The check is whether the gap between the KRW 17 billion guidance and KRW 12.1 billion January–September operating profit was filled in Q4, and whether net profit attributable to controlling shareholders stayed positive.

  3. March 2027

    Filing of the 2026 annual report. The points to verify are how non-operating items, income tax and the effect of removing Hecton Project from consolidation are reflected in the annual figures.

  4. March 2027

    The planned full launch of the cloud EMR and the opening of the external service gateway. The launch timing and the number of third-party services onboarded will show how fast the Medical OS revenue model is realized.

  5. Second half of 2027

    The planned launch of a consumer personal health assistant linked to Ddocdoc. It will show whether revenue can be generated from direct patient touchpoints.

12

Overall view

GC MediAI builds add-on solutions, data services and platform integration fees on top of its primary care EMR customer base.

Annual operating profit has grown for two consecutive years since the 2023 low, and preliminary January–September 2026 operating profit was KRW 12.1 billion, up 165.9% year on year, as announced by the company.

However, revenue growth over the same period was only 6.5%, and the 2026 revenue guidance was lowered to KRW 174.4 billion due to the deconsolidation of Hecton Project.

Net profit attributable to controlling shareholders turned positive in 2025, but the four-quarter total is only KRW 2.6 billion and the sign has changed several times.

Bullish factors are the recovery in operating margin and the path to AI and platform monetization, while bearish factors are slower top-line growth, earnings volatility, and the concentration of AI paid revenue after 2027.

The checkpoints are the 6,000-site adoption target for Uisarang AI at year-end 2026, the preliminary Q4 2026 results in early 2027, and the 2026 annual report and cloud EMR launch in March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. biz.heraldcorp.com
  2. alphabiz.co.kr
  3. consumuch.com
  4. insightkorea.co.kr
  5. newsway.co.kr
  6. meconomynews.com
  7. press9.kr
  8. view.asiae.co.kr
  9. inthenews.co.kr
  10. biz.heraldcorp.com
  11. ngonews.kr
  12. pharmnews.com
  13. betanews.net
  14. press.yitoday.com
  15. newsclaim.co.kr
  16. kpanews.co.kr
  17. newscj.com
  18. specialtimes.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis